A world-first clinical trial comparing 2.5-yearly cytology with five-yearly HPV screening is currently underway
A world-first clinical trial comparing 2.5-yearly cytology with five-yearly HPV screening is currently underway.
The Compass Trial is being undertaken at general practices, led by researchers at the Victorian Cytology Service and The Cancer Council NSW.
The randomised controlled trial compares 2.5-yearly cytology-based cervical screening with 5-yearly primary HPV screening in Australian women aged 25-64.
It will assist the development of new guidelines, says Dr Lara Roeske, a liaison physician at the Victorian Cytology Service and a general practitioner in Melbourne.
In this video, Dr Roeske discusses:
– What is The Compass Trial?
– How can practices participate in The Compass Trial?
